ArticleTrials2026
The effectiveness of a motivational interviewing-based intervention for reducing depressive symptoms after stroke compared to an attention control and usual care: study protocol for a multi-centre randomised controlled trial (COMMITS).
Article in Trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDepression affects almost 60% of stroke survivors, impacting on recovery and quality-of-life. Depression may be treated with medication or talk-based therapies. One randomised controlled trial showed a talk-based therapy called motivational interviewing-based intervention (MIBI) delivered early after stroke reduced depressive symptoms at 3 and 12 months post-stroke compared with receiving usual care alone. However, it was unclear if the benefit was due to the specific MIBI components or simply the additional attention received. This trial aims to determine the effect of MIBI plus usual care on reducing depressive symptoms post-stroke, relative to usual care (UC), and to an attention control (AC) (social attention without therapeutic content, i.e. general conversation).
methodsPatients admitted following acute stroke meeting the study eligibility criteria (not currently receiving talk-based therapy and not currently having severe depression) will be recruited across 18 UK hospitals within 28 days of stroke. A total of 1287 participants will be randomised on a 1:1:1 ratio into three groups: MIBI + UC; AC + UC; UC. Participants in MIBI + UC and AC + UC will additionally have remote (telephone/online) sessions with MIBI therapists or AC providers respectively, for four 45-min weekly sessions, beginning within 6 weeks of randomisation. Participant self-report measures of depression (primary outcome, Patient Health Questionnaire (PHQ-9) at 3 months) and quality-of-life will be collected at baseline, 6 weeks and 3 months post-randomisation. The proposed mechanism of effect, via participants' self-efficacy and confidence, and the impact of MIBI dose and/or therapeutic alliance on outcome will also be explored. If benefit of MIBI + UC over UC is demonstrated, mixed effects regression will be fitted to outcome data from all three arms, and appropriate parametrisation with MIBI + UC as the reference group. A mixed-methods process evaluation comprising quantitative assessment of intervention adherence and fidelity and semi-structured interviews with a purposive sample of study participants (n ~ 18) and MIBI/AC staff (n ~ 15) will explore participation, acceptability, and considerations for implementation. An economic evaluation will explore cost-effectiveness. DISCUSSION: The results will inform whether any observed improvements in mood are a natural change over time, due to attention, or a therapeutic change attributable to MIBI. If MIBI is shown to effectively reduce depressive symptoms, the process evaluation will inform implementation of the intervention into clinical care.
trial registrationISRCTN, ISRCTN17065351. Registered 01/02/2022, https://www.isrctn.com/ISRCTN17065351 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.